Stock Market Update - February 13, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. RIME - Algorhythm Holdings, Inc.
Price: $3.48 | Change: +222.22% ($2.4)
RIME:NASDAQ just saw an astonishing 222.22% gain, driven by Algorhythm Holdings, Inc.'s significant advancements in its AI-driven logistics platform, SemiCab. This system promises to radically transform freight operations. It allows customers to scale freight volumes by an impressive 300% to 400% without increasing staff, and enables individual operators to manage over 2,000 loads annually—a huge leap from the industry norm of approximately 500.
The SemiCab platform automates complex network decisions, leading to lower costs and reduced administrative overhead. Crucially, it claims to reduce "empty freight miles"—a major industry inefficiency—by over 70%, addressing a colossal global problem estimated to cost up to $700 billion annually. This technological breakthrough triggered a dramatic selloff in traditional freight stocks, while RIME's shares exploded higher.
Further bolstering investor confidence, Algorhythm reported an annualized revenue run rate of $9.7 million by December 2025, marking an impressive 300% year-over-year growth. The company also secured new major contracts, showcasing strong market validation for its innovative solution.
2. JDZG - JIADE Limited
Price: $3.81 | Change: +125.44% ($2.12)
JDZG saw its stock price surge an impressive 125.44% around February 12-13, 2026. This significant jump was primarily driven by strategic corporate developments and encouraging financial news from JIADE Limited. Key catalysts included a major strategic acquisition aimed at expanding the company's European operations, alongside an announced expansion of a strategic partnership.
The acquisition is anticipated to boost revenue streams and market share, while the partnership expansion is expected to propel JDZG into new territories, solidifying its global presence. Adding to the optimism, the company reported a notable revenue increase to approximately $18.7 million with robust pretax profit margins of 41.6%. A strong balance sheet, free of long-term debt, further underscored its financial health and capacity for future initiatives, collectively fueling investor confidence in the company's direction.
3. HEPA - Hepion Pharmaceuticals, Inc.
Price: $0.064 | Change: +87.41% ($0.02985)
HEPA:NASDAQ – While an 87.41% gain might have been hoped for, the reality for Hepion Pharmaceuticals around mid-February 2026 was quite different. Instead of a surge, HEPA was experiencing a significant decline, trading at just pennies per share and showing strong bearish signals. The stock had shed over 38% since the beginning of 2026, continuing a prolonged downtrend that reflected the company's precarious financial position.
A major reason for this struggle was the company's non-compliance with Nasdaq listing requirements, prompting a proposed merger with Pharma Two B Ltd. This strategic move aimed to shift the combined entity's focus to a Parkinson's Disease treatment (P2B001) and ultimately stave off potential delisting and bankruptcy. A new CEO was also appointed in January 2026, tasked with a strategic repositioning towards precision diagnostics.
This situation highlights the intense challenges small biotech firms can face, often necessitating dramatic strategic shifts and corporate restructuring to ensure survival and secure a path forward for their drug candidates.
4. MLEC - Moolec Science S.A.
Price: $8.63 | Change: +69.22% ($3.53)
MLEC experienced an impressive 69.22% gain around February 14, 2026, following a significant operational milestone. Moolec Science, known for its molecular farming platform, announced a breakthrough with its U.S. GLASO1 safflower platform. During commercial-scale operations, this specialized safflower achieved an impressive approximately 45% concentration of gamma-linolenic acid (GLA).
This high concentration of GLA – a valuable functional lipid used in nutrition and dietary supplements – is a crucial validation of Moolec's plant-engineered technology. The company also reported a substantial 57% year-over-year increase in average yield from its 2025 safflower campaign, further demonstrating the effectiveness and scalability of its innovation.
This development is expected to significantly strengthen Moolec's position within the U.S. nutrition and dietary supplements market. With a growing demand for high-concentration, traceable, and plant-engineered ingredients, Moolec's success in producing high-quality GLA positions it as a notable player in this evolving space.
5. ATOM - Atomera Incorporated
Price: $3.92 | Change: +64.02% ($1.53)
ATOM soared 64.02%, experiencing a significant surge around February 14, 2026. This impressive move was primarily driven by Atomera's major technical advancements and new commercial engagements within the semiconductor industry.
The company announced a breakthrough in demonstrating its Mears Silicon Technology (MST) can be manufactured on advanced Gate-All-Around (GAA) transistor structures. This is a crucial step for building the next generation of powerful chips, especially for high-demand applications like AI, making their technology highly appealing to leading chip foundries. Atomera also initiated its first commercial customer engagement for Gallium Nitride (GaN) on silicon, diversifying its market opportunities.
What makes this particularly interesting is that the market reacted positively despite the company reporting continued financial losses and minimal revenue in its latest results. Investors appear to be focusing on these strategic technological milestones and the anticipated future licensing and commercial agreements, signaling strong belief in Atomera's underlying technical progress and early commercial traction.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.